Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 公司前身为成立于2008年7月4日的安旭有限。注册资本为30.00万元，裘金芬担任安旭有限法定代表人。2008年7月3日，浙江岳华会计师事务所出具《验资报告》（浙岳华验字[2008]第0767号），经审验，截至2008年6月23日，安旭有限已收到股东裘金芬、裘科斌缴纳的注册资本合计30.00万元，均系货币出资。上述出资事项业经信永中和复核确认并出具XYZH/2020HZA20035号《验资复核报告》。 2019年8月26日，安旭有限召开股东会，决议以2019年6月30日为审计和评估基准日由有限责任公司整体变更为股份有限公司，以截至2019年6月30日经审计净资产135,965,695.69元为基础，将净资产中的46,000,000元折合为注册资本46,000,000元，每股面值1.00元人民币，共计4,600万股，净资产超过注册资本的部分89,965,695.69元计入股份公司的资本公积。根据万隆（上海）资产评估有限公司出具的《资产评估报告》。2019年8月28日，公司就本次整体变更办理完毕工商变更登记手续，取得股份公司营业执照，统一社会信用代码913301066767726252，名称由杭州安旭科技有限公司变更为杭州安旭生物科技股份有限公司，企业类型由有限责任公司（自然人投资或控股）变更为其他股份有限公司（非上市公司）。 公司成立于2008年，专注于POCT试剂及仪器的研发、生产与销售，拥有抗原抗体自主研发生产的生物原料技术平台，以及成熟的免疫层析及干式生化诊断技术平台，发展形成了覆盖毒品检测、传染病检测、慢性病检测、妊娠检测、肿瘤检测、心肌检测、生化检测、过敏原检测等八大领域的POCT试剂，产品远销美国、德国、英国、加拿大、俄罗斯、墨西哥、泰国、印尼及波兰等多个国家，已成为国内少数几家在POCT国际市场能够与跨国体外诊断行业巨头竞争的中国体外诊断产品供应商之一。 公司在发展过程中非常重视技术创新和产品升级，并实现了大量研发成果的转化。2013年12月，公司被浙江省科学技术厅认定为“浙江省科技型中小企业”；2015年7月，公司研发中心被杭州市科学技术委员会评为“杭州市企业高新技术研究开发中心”；2015年9月，公司被认定为“国家高新技术企业”；2016年12月，公司研发中心被浙江省科学技术厅评为“省级高新技术企业研究开发中心”；2021年8月，公司被认定为“国家级专精特新小巨人企业”。
Main Business POCT试剂及仪器的研发、生产与销售
Legal Representative 凌世生
Top Executives
董事长：凌世生
副董事长：姜学英
董事：黄银钱,董文坤,姜学英
独立董事：章国标,周娟英,马卫民
Top 5 Shareholder
Shareholder name Nature Holding Date
杭州艾旭控股有限公司限售股26.87%30/09/2024
凌世生限售股25.12%30/09/2024
马华祥限售股11.62%30/09/2024
丽水创圣企业管理合伙企业（有限合伙）限售股9.37%30/09/2024
姜学英限售股2.00%30/09/2024
Company Secretary 韩钧
Solicitors 上海市锦天城律师事务所
Auditors 信永中和会计师事务所（特殊普通合伙）
Tel No 0571-85391552
Fax No 0571-88865920
Website www.diareagent.com
Email jun.han @diareagent.com
Company Address
Register: 浙江省杭州市莫干山路1418-50号4幢3层（上城科技工业基地）
Office: 浙江省杭州市莫干山路1418-50号4幢5层
Listing Date 18/11/2021
Shares Capital
Shares Capital: 127,082,805
Total A Share: 127,082,805
Listed A Share: 127,082,805
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.110
DPS(RMB)* ¥ 0.400
NBV Per Share(RMB)* ¥ 40.206
Market Capitalization(RMB) 5.109B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.